研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

PER3 启动子高甲基化与泛癌的进展相关。

PER3 promoter hypermethylation correlates to the progression of pan-cancer.

发表日期:2024 Oct 14
作者: Yaoxu Li, Wenjuan Li, Jinhai Deng, Mingzhu Yin
来源: Clinical Epigenetics

摘要:

恶性肿瘤细胞表现出周期昼夜节律调节因子 3 (PER3) 表达减少。然而,癌症中PER3表达变化的潜在机制以及PER3在肿瘤进展中的具体功能仍然知之甚少。我们探索了多个公共数据库,进行了生物信息学分析,并进行了体外和体内实验进行验证。我们发现 PER3 表达在大多数类型的癌症中均下降,并且 PER3 下调与 8 种癌症的不良预后相关。 11 种癌症中 PER3 启动子甲基化水平升高。启动子高甲基化(CpG 岛 [CGI] cg12258811 和 cg14204433)与六种癌症(乳腺浸润性癌、结肠腺癌、头颈鳞状细胞癌、肾肾乳头状细胞癌 [KIRP]、肺腺癌 [LUAD]、和子宫体子宫内膜癌)。 CGI cg12258811 高甲基化与生存时间缩短和晚期癌症阶段相关。此外,亚硫酸氢盐焦磷酸测序测定证实了CGI cg12258811高甲基化及其与PER3表达的负相关。体外和体内实验表明 PER3 抑制 KIRP 和 LUAD 进展。地西他滨通过降低启动子 (cg12258811) 甲基化水平来增强 PER3 表达并抑制 KIRP 细胞功能。我们的研究结果推进了对癌症中 PER3 表达变化的机制理解,并证实了 PER3 高甲基化和下调的肿瘤相关功能。© 2024。作者( s)。
Malignant cells exhibit reduced period circadian regulator 3 (PER3) expression. However, the underlying mechanisms of variations in PER3 expression in cancers and the specific function of PER3 in tumor progression remain poorly understood.We explored multiple public databases, conducted bioinformatics analyses, and performed in vitro and in vivo experiments for validation. We found PER3 expression was decreased in most types of cancers, and PER3 downregulation was associated with a poor prognosis in 8 types of cancer. PER3 promoter methylation levels were increased in 11 types of cancer. Promoter hypermethylation (CpG islands [CGIs] cg12258811 and cg14204433) correlated with decreased PER3 expression in six cancers (breast invasive carcinoma, colon adenocarcinoma, head and neck squamous cell carcinoma, kidney renal papillary cell carcinoma [KIRP], lung adenocarcinoma [LUAD], and uterine corpus endometrial carcinoma). CGI cg12258811 hypermethylation was associated with reduced survival time and advanced cancer stages. Moreover, the bisulfite pyrosequencing assay confirmed CGI cg12258811 hypermethylation and its negative correlation with PER3 expression. In vitro and in vivo experiments demonstrated that PER3 inhibited KIRP and LUAD progression. Decitabine enhanced PER3 expression and inhibited KIRP cell functions by reducing promoter (cg12258811) methylation level.Our findings advanced the mechanistic understanding of variations in PER3 expression in cancers and confirmed the tumor-associated function of PER3 hypermethylation and downregulation.© 2024. The Author(s).